NCT04266249

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2020-03-13Est. Completion: 2026-10-31

Enrollment target: 2,175 participants

Locations

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
Alaska Women's Cancer Care, Anchorage, Alaska, United States
Anchorage Oncology Centre, Anchorage, Alaska, United States
Katmai Oncology Group, Anchorage, Alaska, United States
Providence Alaska Medical Center, Anchorage, Alaska, United States
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
Kingman Regional Medical Center, Kingman, Arizona, United States
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States
Banner University Medical Center - Tucson, Tucson, Arizona, United States
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8HER2-Positive Breast CarcinomaInvasive Breast Carcinoma

This phase II trial tests how well an imaging procedure called fludeoxyglucose F-18 (FDG) positron emission tomography/c…

Birmingham, United StatesEst. completion May 31, 2027

Anatomic Stage IV Breast Cancer AJCC v8Hormone Receptor Positive Breast CarcinomaMetastatic Breast Carcinoma

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.